Calcium Ionophore-Activated Neutrophils Prestimulated with Endotoxin Increase Pulmonary Arterial Pressure and Vascular Leakage in Isolated Perfused Rat Lungs: Role of Platelet-Activating Factor

References

• Lynn W S. Inflammatory Cells and Lung Disease. CRC Press Inc, Boca Raton, FL 1983
   Google Scholar
• Suttorp N, Simon L W. Lung cell oxidant injury: Enhancement of polymorphonuclear leukocyte-mediated cytotoxicity in lung cells exposed to sustained in vitro hyperoxia. J Clin Invest 1982; 70: 342–350
   PubMed Web of Science ®Google Scholar
• Walsh C E, Waite M B, Thomas M J, DeChatelet L R. Release and metabolism of arachidonic acid in human neutrophils. J Biol Chem 1981; 256: 7228–7234
   PubMed Web of Science ®Google Scholar
• Lindahl M, Bruhn R, Tagesson C. Lysophosphatidylcholine and the inflammatory action of neutrophils. Scand J Clin Lab Invest 1988; 48: 303–311
   PubMed Web of Science ®Google Scholar
• Lotner G Z, Lynch J M, Betz S J, Henson P M. Human neutrophil-derived platelet-activating factor. J Immunol 1980; 124: 676–684
   PubMed Web of Science ®Google Scholar
• Movat H Z. The acute inflammatory reaction. Inflammation, Immunity, and Hypersensitivity, H Z Movat. Harper & Row, New York 1979; 1–163
   Google Scholar
• Lindahl M, Hede A R, Tagesson C. Lysophosphatidylcholine increases airway and capillary permeability in the isolated perfused rat lung. Exp Lung Res 1986; 11: 1–12
   PubMed Web of Science ®Google Scholar
• Seeger W, Wolf H, Stähler G, Neuhof H, Roka L. Increased pulmonary vascular resistance and permeability due to arachidonate metabolism in isolated rabbit lungs. Prostaglandins 1982; 23: 157–173
   PubMed Web of Science ®Google Scholar
• Tate R M, Van Benthuysen K M, Shashy D M, McMurtry I F, Repine J E. Oxygen radical-mediated permeability edema and vasoconstriction in isolated perfused rabbit lungs. Am Rev Respir Dis 1982; 126: 802–806
   PubMed Web of Science ®Google Scholar
• Carpenter L J, Roth R A. Involvement of thromboxane in injury to isolated rat lungs perfused with phorbol myristate acetate in the presence and absence of neutrophils. Toxicol Appl Pharmacol 1987; 91: 33–45
   PubMed Web of Science ®Google Scholar
• Carpenter L J, Johnson K J, Kunkel R G, Roth R A. Phorbol myristate acetate produces injury to isolated rat lungs in the presence and absence of perfused neutrophils. Toxicol Appl Pharmacol 1987; 91: 22–32
   PubMed Web of Science ®Google Scholar
• Ferrante A, Thong Y H. Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leukocytes from human blood by the Hypaque-Ficoll method. J Immunol Methods 1980; 36: 109–117
   PubMed Web of Science ®Google Scholar
• Hede A R, Post C. Trichloroethylene and halothane inhibit the pulmonary uptake of 5-hydroxytryptamine in isolated perfused rat lung. Biochem Pharmacol 1982; 31: 353–358
   PubMed Web of Science ®Google Scholar
• Braquet P. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): A powerful PAF-acether antagonist isolated from Ginkgo biloba. Adv Prostaglandin Thromboxane Leukotriene Res 1986; 16: 179–198
   PubMedGoogle Scholar
• Lanni C, Becker E L. Inhibition of neutrophil phospholipase A2 by p-bromophenylacyl bromide, nordihydroguaiaretic acid, 5, 8, 11, 14-eicosatetrayenoic acid and quercetin. Int Arch Allergy Appl Immunol 1985; 76: 214–217
   PubMedGoogle Scholar
• Otamiri T, Lindahl M, Tagesson C. Phospholipase A2 inhibition prevents muco-sal damage associated with small intestinal ischaemia in rats. Gut 1988; 29: 489–494
   PubMed Web of Science ®Google Scholar
• Fisher A B, Dodia C, Linask J. Perfusate composition and edema formation in isolated rat lungs. Exp Lung Res 1980; 1: 13–21
   PubMed Web of Science ®Google Scholar
• Chap H, Mauco G, Simon M F, Benveniste J, Douste-Blazy L. Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets. Nature 1981; 289: 312–314
   PubMed Web of Science ®Google Scholar
• Worthen G S. Lipid mediators, neutrophils, and endothelial injury. Am Rev Respir Dis 1987; 136: 455–458
   PubMed Web of Science ®Google Scholar
• Patterson C E, Barnard J W, Lafuze J E, Hull M T, Baldwin S J, Rhoades R A. The role of activation of neutrophils and microvascular pressure in acute pulmonary edema. Am Rev Respir Dis 1989; 140: 1052–1062
   PubMed Web of Science ®Google Scholar
• Olsen U B, Bille-Hansen V. Endotoxin pretreatment enhances neutrophil FMLP-receptor binding and activity in guinea pigs. Agents Actions 1987; 21: 177–183
   PubMedGoogle Scholar
• Smedly L A, Tonnesen M G, Sandhaus R A, Haslett C, Guthrie L A, Johnston R B, JR, Henson P M, Worthen G S. Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest 1986; 77: 1233–1244
   PubMed Web of Science ®Google Scholar
• Haslett C, Worthen G S, Giclas P C, Morrison D C, Henson J E, Henson P M. The pulmonary vascular sequestration of neutrophils in endotoxemia is initiated by an effect of endotoxin on the neutrophils in the rabbit. Am Rev Respir Dis 1987; 136: 9–18
   PubMed Web of Science ®Google Scholar
• Worthen G S, Seccombe J F, Clay K L, Guthrie L A, Johnston R B, Jr. The priming of neutrophils by lipopolysaccharide for production of intracellular platelet-activating factor. Potential role in mediation of enhanced superoxide secretion. J Immunol 1988; 140: 3553–3559
   PubMed Web of Science ®Google Scholar
• Voelkel N F, Simpson J, Worthen S, Reeves J T, Henson P M, Murphy R C. Platelet-activating factor causes pulmonary vasoconstriction and edema via independent leukotriene formation. Adv Prostaglandin Thromboxane Leukotriene Res 1983; 12: 179–183
   PubMedGoogle Scholar
• Handley D A, Arbeency C M, Lee M L, van Valen R G, Saunders R N. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacol 1984; 8: 137–142
   PubMedGoogle Scholar
• Touvay C, Vilain B, Taylor J E, Etienne A, Braquet P. Proof of the involvement of platelet-activating factor (PAF-acether) in pulmonary complex immune systems using a specific PAF-acether receptor antagonist: BN 52021. Prog Lipid Res 1986; 25: 277–288
   PubMed Web of Science ®Google Scholar
• Koltai M, Lepran I, Scekeres L, Viossat I, Chabrier E, Braquet P. Effect of BN 52021, a specific PAF-acether antagonist, on cardiac anaphylaxis in Langendorff hearts isolated from passively sensitized guinea pigs. Eur J Pharmacol 1986; 130: 133–136
   PubMed Web of Science ®Google Scholar
• Hwang S-B, Lam M-H, Shen T Y. Specific binding sites for platelet-activating factor in human lung tissues. Biochem Biophys Res Commun 1985; 128: 972–979
   PubMed Web of Science ®Google Scholar
• Griffith T M, Edwards D H, Lewis M J, Newby A C, Henderson A H. The nature of endothelium-derived vascular relaxant factor. Nature 1984; 308: 645–647
   PubMed Web of Science ®Google Scholar